Norden Group LLC Acquires 1,793 Shares of Amgen Inc. $AMGN

Norden Group LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 26.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,504 shares of the medical research company’s stock after purchasing an additional 1,793 shares during the quarter. Norden Group LLC’s holdings in Amgen were worth $2,784,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. West Family Investments Inc. raised its position in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 30 shares during the period. Viawealth LLC lifted its stake in shares of Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after buying an additional 30 shares during the last quarter. LOM Asset Management Ltd boosted its holdings in shares of Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after buying an additional 30 shares during the period. Sittner & Nelson LLC grew its stake in Amgen by 0.4% in the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after buying an additional 30 shares during the last quarter. Finally, TAGStone Capital Inc. grew its stake in Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after buying an additional 32 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AMGN has been the topic of several research analyst reports. Daiwa Securities Group increased their price target on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Rothschild & Co Redburn lifted their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Finally, Royal Bank Of Canada boosted their price target on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $354.60.

Amgen Stock Down 0.2%

Shares of NASDAQ AMGN opened at $353.16 on Friday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The stock has a market capitalization of $190.38 billion, a P/E ratio of 24.82, a PEG ratio of 3.51 and a beta of 0.45. The stock’s fifty day moving average is $362.22 and its 200 day moving average is $329.40.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.